Abbott Laboratories Underperforming the S&P 500: A Closer Look

Abbott Laboratories' (ABT) stock has underperformed the S&P 500 Index, declining 2.9% over the past three months compared to the index's 5.1% gains. The company's Q3 results showed a 6.9% YoY increase in net sales to $11.4 billion, but missed consensus estimates. Despite this, analysts remain optimistic about the stock's long-term prospects, with a "Strong Buy" consensus rating and a mean price target of $146.69, suggesting a 14.6% upside potential from current price levels.